The Precision Medicine Platform for Common Disease

Talk with us

Allelica is a global life sciences company powering the healthcare and pharmaceutical industries with comprehensive solutions for the development and commercialization of clinical genetic tests. Uniquely positioned as innovators in genetic risk prediction and experts in medical devices, Allelica offers a cutting-edge quality management system, specifically designed to develop and implement new genetics based assays.

What we do

img

Streamline Genetic Test Development with Expert Precision

Allelica’s agile quality management system (QMS) is tailored for clinical genetic test development, providing biotech and pharmaceutical companies with the expertise and advanced software needed to bring new assays from concept to market. Our comprehensive platform supports every stage of the process, from design and validation to regulatory compliance and commercialization, ensuring that your genetic tests meet rigorous clinical and industry standards. Partner with Allelica to accelerate your pipeline and deliver innovative genetic solutions with confidence.

img

Drive Better Patient Outcomes with Comprehensive Genetic Risk Assessment

Allelica’s advanced PRS technology equips physicians with the tools needed to advance precision medicine. By incorporating genetic risk scores into routine practice, you can identify high-risk patients across multiple disease categories, tailor interventions more effectively, and lead the way in personalized healthcare.

img

Secure, Scalable Bioinformatics Solutions for Your Laboratory

Allelica’s bioinformatics platform empowers laboratories to bring clinical PRS, pharmacogenetics, and carrier screening analyses in-house with confidence. Available as both cloud-based and on-premise solutions when data cannot leave the building. Allelica software is designed for seamless integration into your existing workflows. With customizable panels and multilingual, white-label reporting, Allelica provides the flexibility and scalability needed to meet your lab’s specific needs while maintaining the highest standards of security and performance. Elevate your lab's capabilities with Allelica’s advanced, adaptable tools.

imgimgimg

Allelica ISO Certification

img img

Trusted By

imgimgimgimg
imgimgimgimg
imgimgimg
img

"With this agreement, Merck confirms its strong commitment to advancing science and technology in the area of cardiovascular disease"

Read more →

Antonio Messina, General Manager, Merck Biopharma

Latest news

img Allelica multi-ancestry PRS published in Nature Communications

Results published by Allelica scientists in Nature Communications demonstrate the clinical utility of polygenic risk scores across multiple ancestry groups.The publication adds to growing evidence of the clinical value of PRS in cardiovascular disease risk assessment, showing that adding PRS to traditional models improves their precision and accuracy.

img Baylor & Allelica present clinical workflow for PRS testing at ASHG

Allelica presented collaborative results with Baylor College of Medicine at the American Society of Human Genetics Annual Meeting 2023. George Busby, Allelica CSO, presented the results in the poster titled “Complete end-to-end workflow for implementing clinical polygenic risk scores”.

img Allelica launches the Allelica Precision Server

Allelica announces the release of the Allelica Precision Server (APS) for CLIA-compliant, on-premises analysis and clinical reporting of polygenic risk score, pharmacogenomics and carrier screening. APS is now available for medical laboratories and healthcare providers.

img Allelica participates in BiotechX Europe 2023

The Allelica team met with leaders in the pharmaceutical industry and biotechnology at the annual BioTechX conference in Basel, Switzerland. PRS is increasingly gaining traction among pharma and biotech companies for its ability to stratify clinical trial populations and identify new drug targets.

img PRS cost-effectiveness results published in Frontiers

Results published by Allelica researchers in Frontiers in Public Health reveal that integrating PRS testing into workplace health programs cuts costs for employers and improves quality of life for employees. Authors found that Allelica's workplace program integrating PRS with the standard of care, cardioriskSCORE, significantly outperformed programs without PRS.

img Allelica delivers oral presentation, three poster presentations at ESHG 2023

The Allelica team showcased exciting PRS results at the European Society of Human Genetics Conference 2023. Posters included: Low-coverage genotyping-by-sequencing with accurate long HiFi reads and optimized imputation (presented in collaboration with PacBio), Recalibrating polygenic risk scores to country-specific incidence, and Analyses of polygenic risk scores that consider individual-level admixture proportions outperform single ancestry approaches.

img Clinical breast cancer PRS Results presented at ASCO 2023

Dr. Daniel Morganstern of Hartford Healthcare presented results integrating Allelica’s multi-ancestry PRSs into risk assessments at the American Society of Clinical Oncology Annual Meeting. Findings revealed the value PRS provides in clinical risk assessments for breast cancer.

img Allelica Research Published in the Journal of the American Heart Association

A health economics study [Integrating a Polygenic Risk Score for Coronary Artery Disease as a Risk‐Enhancing Factor in the Pooled Cohort Equation: A Cost‐Effectiveness Analysis Study] has been published in the Journal of the American Heart Association. The study, performed by Allelica, in collaboration with experts from Illumina and the University of Sydney, analyzed the cost-effectiveness of PRS in heart disease risk assessments and found that PRS is cost-saving in US health systems.

img Allelica CAD PRS Research in Circulation

Allelica researchers identified a critical interaction between PRS for coronary artery disease (CAD) and LDL cholesterol level. Their discovery has major implications for clinical decision-making in primary prevention strategies. The research is now available in the American Heart Association Journal, Circulation.

img Allelica Obtains ISO Certification

Allelica continues to set the industry standard of clinical-grade Polygenic Risk Score analysis with the addition of two key ISO certifications. ISO 13485 and ISO 9001 certify that Allelica applies medical device quality management processes every step of the way.

img

Our Principles

img Data Driven

Our products are developed and validated using world class datasets and state-of-the-art technology to ensure the highest level of quality.

img Scientific Rigor

We are a group of international scientists and researchers committed to maintaining standards of academic excellence every step of the way.

img Human-centricity

Everything we do works towards our common goal of providing tangible improvement in preventive healthcare to help humans live a longer, healthier life.